Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Comparisons of Adherence, Efficacy and Price between Sitagliptin/Metformin Fixed-dose Combination Tablets and Concomitant Administration of Sitagliptin and Metformin in Type 2 Diabetes Mellitus Patients

제2형 당뇨병 환자에서 시타글립틴과 메트포민 고정 복합제 투여와 단일제 병용간의 복약 순응도, 효과 및 약가에 대한 비교 연구

  • Park, Ji Hye (Division of Pharmaceutical Services, Asan Medical Center) ;
  • Lee, Byung Koo (College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University) ;
  • Kim, Jae Youn (Division of Pharmaceutical Services, Asan Medical Center) ;
  • Gwak, Hye Sun (College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University)
  • Received : 2014.07.22
  • Accepted : 2014.09.12
  • Published : 2014.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: This study was conducted to compare the adherence, clinical and economical utility of fixed-dose combination tablets of sitagliptin/metformin with concomitant administration of sitagliptin and metformin in patients with type 2 diabetes mellitus. Methods: Adherence was measured as the medication possession ratio (MPR) of ${\geq}80%$, and MPR was calculated as the number of total prescription days divided by the total treatment period. Hemoglobin $A_{1C}$ ($HbA_{1c}$) differences between baseline and predetermined periods were analyzed. Proportions of patients who achieved $HbA_{1c}$ less than 6.5% for three or more consecutive times were compared. To evaluate cost-effectiveness, prices of sitagliptin, metformin and sitagliptin/metformin tablets were investigated. Results: More than 90% of patients showed adherence in both groups (92.0% in fixed-dose combination group vs 95.9% in concomitant administration group), and there was no statistically significant difference (P = 0.113). Proportion of patients with HbA1c less than 6.5% for three or more consecutive times tended to be somewhat higher in fixed dose combination group than in concomitant administration group without a statistically significant difference (32.6% vs. 28.0%, P = 0.344). Total price of metformin and sitagliptin was cheaper up to 222 KRW in the case of fixed-dose combination tablets compared to the case of concomitant administration. Conclusion: The sitagliptin/metformin fixed-dose combination tablet had a similar patient adherence and was not significantly different in efficacy to the concomitant administration of each component. In terms of drug prices, fixed-dose combination tablets were cheaper than concomitant administration of each tablet.

Keywords

References

  1. Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C. Lifestyle Interventions for Patients With and at Risk for Type 2 DiabetesA Systematic Review and Meta-analysis.Ann Intern Med 2013;159(8):543-51. https://doi.org/10.7326/0003-4819-159-8-201310150-00007
  2. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(18):1343-50. https://doi.org/10.1056/NEJM200105033441801
  3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359(15):1577-89. https://doi.org/10.1056/NEJMoa0806470
  4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-53. https://doi.org/10.2337/diacare.27.5.1047
  5. Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet 2010;375(9712):408-18. https://doi.org/10.1016/S0140-6736(09)60937-5
  6. American Diabetes Association. American Diabetes Association (ADA) guidelines: clinical practice recommendations. Diabetes Care 2006;29(Suppl. 1):S1-S85. https://doi.org/10.2337/diacare.29.01.06.dc05-1058
  7. Oh JY. Treatment guideline for diabetes. Korean J Intern Med. 2008;75(3):249-56.
  8. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35(6):1364-79. https://doi.org/10.2337/dc12-0413
  9. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D.Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;20(3):CD002966.
  10. Miller, Shannon A., and Erin L. St Onge. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother 2006;40(7-8):1336-43. https://doi.org/10.1345/aph.1G665
  11. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24(3):460-7. https://doi.org/10.1016/S0149-2918(02)85047-0
  12. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11(1):44-7. https://doi.org/10.1111/j.1524-4733.2007.00213.x
  13. Vermeire E, Wens J, Van Royen P, Biot Y, Hearnshaw H, Lindenmeyer A. Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;18(2):CD003638.
  14. Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014;348:g3318. https://doi.org/10.1136/bmj.g3318
  15. Bramlage P, Ketelhut R, Fronk EM, et al. Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide. Clin Drug Investig 2014;34(6):403-11. https://doi.org/10.1007/s40261-014-0188-z
  16. Gu N, Kim BH, Rhim H, et al. Comparison of the bioavailability and tolerability of fixed-dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy Korean volunteers. ClinTher 2010;32(7):1408-18.
  17. Migoya EM, Miller JL, Gutierrez M, et al. Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects. Clin Drug Investig 2010;30(12):855-66. https://doi.org/10.1007/BF03256914
  18. He YL, Paladini S, Sabia H, et al. Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects. Int J ClinPharmacolTher 2008;46(5):259-67.
  19. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004;27(9): 2149-53. https://doi.org/10.2337/diacare.27.9.2149
  20. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014;37(suppl 1):S14-80. https://doi.org/10.2337/dc14-S014